Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study.

Currently, Gilead has three ongoing Phase 3 studies investigating Trodelvy across HER2- (IHC 0, IHC 1+ or IHC 2+/ISH–) mBC, including the upcoming ASCENT-03 pivotal trial in 1L mTNBC patients ...

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 ...

$79.09 0.33 % Gilead Sciences, Inc. GILD on Monday released topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study of Trodelvy (sacituzumab govitecan-hziy) plus Merck & Co Inc’s MRK ...

Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

FOSTER CITY, Calif.-- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy ® (sacituzumab govitecan-hziy) plus ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC ...

FOSTER CITY, Calif.& SANTA MONICA, Calif.---- Gilead Sciences, Inc. will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical Oncology ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA’s MAT2A inhibitor, in combination with Trodelvy, Gilead’s Trop-2 directed ...